Neurobloc (Solstice Neurosciences): Full Drug Profile
- Neurobloc (Solstice Neurosciences) – general information
- Pharmacology of Neurobloc (Solstice Neurosciences)
- Neurobloc (Solstice Neurosciences) for patients
- Neurobloc (Solstice Neurosciences) interactions
- Neurobloc (Solstice Neurosciences) contraindications
- Additional information about Neurobloc (Solstice Neurosciences)
Neurobloc (Solstice Neurosciences) - General Information
Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.
Pharmacology of Neurobloc (Solstice Neurosciences)
Neurobloc (Solstice Neurosciences) inhibits acetylcholine release at the neuromuscular junction via a three stage process: 1) Heavy Chain mediated neurospecific binding of the toxin, 2) internalization of the toxin by receptor-mediated endocytosis, and 3) ATP and pH dependent translocation of the Light Chain to the neuronal cytosol where it acts as a zinc-dependent endoprotease cleaving polypeptides essential for neurotransmitter release.
Neurobloc (Solstice Neurosciences) for patients
Neurobloc (Solstice Neurosciences) Interactions
Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
The effect of administering different botulinum neurotoxin serotypes at the same time or within less than 4 months of each other is unknown. However, neuromuscular paralysis may be potentiated by co-administration or overlapping administration of different botulinum toxin serotypes.
Neurobloc (Solstice Neurosciences) Contraindications
MYOBLOC is contraindicated in patients with a known hypersensitivity to any ingredient in the formulation.
Additional information about Neurobloc (Solstice Neurosciences)
- Neurobloc (Solstice Neurosciences) Indication
For the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.
- Mechanism Of Action
- Neurobloc (Solstice Neurosciences) binds to and cleaves the synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin) which is a component of the protein complex responsible for docking and fusion of the synaptic vesicle to the presynaptic membrane, a necessary step to neurotransmitter release.
- Generic Name
- Botulinum Toxin Type B
- Synonyms
- BTX-B; Botulinum neurotoxin type B precursor
- Drug Category
- Antidystonic Agents
- Drug Type
- Biotech; Approved
- Other Brand Names containing Botulinum Toxin Type B
- Myobloc (Solstice Neurosciences); Neurobloc (Solstice Neurosciences);
- Absorption
- Though pharmacokinetic or ADME studies were not performed, Botulinum Toxin Type B is not expected to be present in the peripheral blood at measurable levels following IM injection at the recommended doses.
- Toxicity (Overdose)
- One unit of Botulinum Toxin Type B corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice.
- Dosage Forms of Neurobloc (Solstice Neurosciences)
- Injection, solution Intramuscular
- Chemical Formula
- C6760H10447N1743O2010S32
- Botulinum Toxin Type B on Wikipedia
- https://en.wikipedia.org/wiki/Botulinum_toxin
- Organisms Affected
- Humans and other mammals
